United States: FDA: Streamlining Regulations For Clinical Research

Title III of the 21st Century Cures Act includes portions of the FDA Device Accountability Act of 2015, Promoting Biomedical Research and Public Health for Patients Act, and FDA and NIH Workforce Authorities Modernization Act. These bills were introduced, but not advanced, by the US Senate.

The prevalence of precision medicine, innovative cures and individualized patient treatments has caused FDA and other regulators to rethink traditional approaches to clinical research. Recent FDA initiatives to encourage adaptive clinical trial designs for novel therapies may signal a move toward greater flexibility regarding the types of clinical evidence and data that is adequate to support a product approval. The clinical trial portions of this legislation focus on streamlining clinical research by harmonizing human subject research protections and informed consent requirements across agencies, so that FDA's human subject regulations are more in line with the human subject regulations of the US Department of Health and Human Services (HHS), which are known as the Common Rule. The bill also offers researchers the flexibility to use non-local institutional review boards (IRB) for investigational and humanitarian use devices and novel clinical trial designs and data in the drug and biological products approval and licensure processes.

3021. Novel Clinical Trial Designs

The Cures legislation requires FDA to hold a public meeting and issue guidance to assist sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs and biological products. Among other items, the new guidance must address the use of such designs to demonstrate the safety and effectiveness of new drugs under the substantial evidence standard (evidence of adequate and well-controlled investigations) for FDA approval of new drugs. The guidance must also address how to submit information from modeling and simulations. This future guidance has the potential to significantly broaden the methodologies of analysis and data that may be used to support the approval and licensure of new products.

In the provision, Congress does not explicitly state whether it intends for the agency to finalize the policies set forth in the 2010 adaptive design draft guidance as-is, or if it expects the agency to make meaningful revisions to that document. However, this section of the legislation suggests that Congress expects FDA to be more flexible in evaluating the evidence of safety and effectiveness to support new drug and biological product applications. Companies with applications pending before the agency (or preparing to submit such applications) should consider leveraging the legislative language to support arguments that safety and effectiveness can be evaluated with more flexible and/or modern trial designs than FDA has traditionally required.

Additionally, sponsors and other stakeholders should consider attending the public meeting and submitting written or oral comments to inform FDA's development of the guidance.

3023. Protection of Human Research Subjects

Effecting a change long sought by researchers, the legislation requires the HHS secretary to harmonize differences between HHS and FDA regulations for the protection of human subject (generally) and vulnerable populations (specifically). The harmonization effort may modernize the regulations to facilitate multi-site and cooperative research projects, avoid regulatory duplication and delays, protect vulnerable populations, and encourage community engagement. Additionally, the legislation encourages sponsors of research that is subject to both HHS and FDA human subject regulations to use a joint or centralized IRB review process. This provision may benefit multi-site trials by consolidating the IRB process.

This section streamlines the process by which human subject research may be reviewed and conducted. This harmonization effort will likely impact the current efforts to amend the Common Rule, which were outlined in a 2015 notice of proposed rulemaking. However, the proposed rulemaking may serve as a guidepost for the effort. For example, the proposed rulemaking would require that cooperative research or multisite studies rely on a single IRB, with limited exceptions, which is consistent with the flexibility proposed under certain circumstances in Section 3056 of the Cures legislation (described below). The extent to which HHS will change any individual provision is unclear at this time, but potential targets are revision of the types of studies that require IRB review and oversight, allowable IRB exemptions, inconsistent definitions (e.g., research, human subject), and various aspects of the informed consent process. For example, harmonization efforts may make it easier for sponsors to obtain and use retrospective analyses of de-identified data, which have historically been exempt from the informed consent requirement under the Common Rule but not expressly exempt under FDA regulations. The possibility of establishing an analogous exemption under FDA requirements may significantly increase the extent to which sponsors rely on such analyses to support product development and other activities. Entities that perform human subject research should monitor HHS's efforts to consult with stakeholders and the Federal Register for additional opportunities to comment on the harmonization process, rulemakings and guidance, as this section arguably provides an opportunity to broaden the exceptions to when informed consent is required for FDA-regulated clinical investigations.

3024. Informed Consent Waiver or Alteration for Clinical Investigators

The legislation allows FDA's informed consent requirements to be waived or altered for trials of investigational drugs or devices if the proposed clinical tests pose no more than minimal risk to the human subjects and include appropriate safeguards to protect the rights, safety and welfare of the subjects. The legislation does not define the phrase "no more than minimal risk" and does not cross-reference any existing HHS or FDA regulations or guidance to provide insight as to how such language should be interpreted by the FDA. Although the phrase is not defined in the US Code, FDA has defined in 21 C.F.R. § 50.52 what constitutes a clinical investigation involving greater than minimal risk to children. Under that regulation, an IRB must find that (1) the risk is justified by the anticipated benefit to the subjects; (2) the relation of the anticipated benefit to the risk is at least as favorable to the subjects as that presented by available alternative approaches; and (3) adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in a separate FDA rule. The FDA's interpretation of the phrase and the language on the "appropriate safeguards" required to protect human subjects will likely require a separate rulemaking or guidance, as the broad statutory language "no more than minimal risk" could be construed in many different ways.

To the extent that FDA's interpretation of "no more than minimal risk" tracks existing HHS regulations on the protection of human research subjects, this section could potentially harmonize FDA's informed consent requirements with existing HHS and National Institutes of Health (NIH) requirements under the Common Rule. For example, in 45 C.F.R. § 46.102, HHS defines "minimal risk" as "the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests." Additional HHS regulations discuss "minimal risk" in the context of research involving not greater than minimal risk to children, research involving greater than minimal risk that presents the prospect of direct benefit to the individual subjects, and research involving greater than minimal risk and no prospect of direct benefit, but that is likely to yield generalizable knowledge about the subject's disorder or condition. FDA may examine the protections in these HHS regulations on "minimal risk" and "greater than minimal risk" to establish appropriate safeguards.

Depending on FDA's interpretation of the phrase "no more than minimal risk," stakeholders that perform, participate in, and/or evaluate investigational drug and device human subject research may have greater freedom to pursue trial designs that were previously impractical under FDA regulations. This legislative change could provide new opportunities for sponsors to use "big data," in particular in retrospective analyses of de-identified data, in submissions to the agency, as such analyses arguably pose no more than a minimal risk to patients.

3056. Institutional Review Board Flexibility

The Cures legislation strikes references to "local" IRBs in the investigational and humanitarian device exemptions, which exempt such devices from requirements including labeling, registration, premarket approval, recordkeeping and reporting. Sponsors, investigators and others involved in a device trial or other device use (e.g., diagnosis or treatment) within the scope of the exemptions will now be allowed to engage a centralized or other non-local IRB for review and approval. This section is consistent with the trend toward centralization of IRB operations and avoidance of duplication of review, especially as associated with multi-site trials.

Sponsors should re-examine their plans for trials and centralize the IRB process insofar as use of a local IRB was intended solely to address FDA requirements. This legislative change may ease the process of beginning a clinical trial and addressing ongoing oversight of a trial. Stakeholders— including investigators, health care providers and medical centers—that administer trials or perform patient services with investigational or humanitarian devices may need to modify existing practices, policies and procedures to allow for review by non-local IRBs.

FDA: Streamlining Regulations For Clinical Research

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.